Dr. Mangla is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Connect with other colleagues in the same hospital or clinic
- Search all U.S. specialist profiles and refer a patient
- Read the latest clinical news and earn CME/CEU credits
Office
UH Cleveland Medical Center
11100 Euclid Ave Department of Medicine-Hematology and Oncology
Cleveland, OH 44106Phone+1 216-844-3951Fax+1 216-844-5234- Is this information wrong?
Summary
- I am a medical oncologist with career interests in melanoma and soft-tissue sarcoma. I am a clinical researcher with a keen interest in bringing immunotherapy related trials. I am PI on several trials which are exploring the role of immunotherapy in both melanoma and sarcoma.
Education & Training
- Cook County Health and Hospitals SystemFellowship, Hematology and Medical Oncology, 2015 - 2018
- Cook County Health and Hospitals SystemResidency, Internal Medicine, 2012 - 2015
- ArMed Forces Medical College PuneClass of 2007, MBBS
Certifications & Licensure
- OH State Medical License 2017 - 2024
- IL State Medical License 2012 - 2023
- American Board of Internal Medicine Internal Medicine
- American Board of Internal Medicine Hematology
- American Board of Internal Medicine Medical Oncology
Awards, Honors, & Recognition
- Certificate of Appreciation for Leading Accrual of Minority Research Participants in 2022 Case Western Reserve University School of Medicine, 2022
Clinical Trials
- A Phase II/III Trial of Nivolumab, Ipilimumab, and GM-CSF in Patients With Advanced Melanoma Start of enrollment: 2015 Nov 23
- CAB-AXL-ADC Safety and Efficacy Study in Adult and Adolescent Patients With Sarcoma Start of enrollment: 2018 Feb 15
- Testing Pembrolizumab Versus Observation in Patients With Merkel Cell Carcinoma After Surgery, STAMP Trial Start of enrollment: 2018 Nov 15
- Join now to see all
Publications & Presentations
PubMed
- Elderberry interaction with pazopanib in a patient with soft‑tissue sarcoma: A case report and literature review.Nikki Agarwal, Ankit Mangla> ;Molecular and Clinical Oncology. 2024 May 1
- Neoadjuvant Dual Checkpoint Inhibitors vs Anti-PD1 Therapy in High-Risk Resectable Melanoma: A Pooled Analysis.Chanmi Lee, Matthew M Mirsky, Margaret Wang, Luke D Rothermel, Richard Hoehn, Jeremy S Bordeaux, Bryan T Carrol, Jason Theuner, Shawn Li, Pingfu Fu, Ankit Mangla, John...> ;JAMA Oncology. 2024 Mar 28
- Is sentinel lymph node biopsy needed for lentigo maligna melanoma?Trisha Lal, Jason E Thuener, Jeremy S Bordeaux, Ankit Mangla, Luke D Rothermel, Richard S Hoehn, Mangla, A., Hanna Kakish> ;Journal of Surgical Oncology. 2024 Mar 1
- Join now to see all
Abstracts/Posters
- Net Clinical Benefit of Low Dose Rivaroxaban in Coronary Heart Disease: A Systematic Review and Meta-AnalysisAnkit Mangla, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
- A Systematic Review and Meta-Analysis of Cardio-Vascular Side Effects with Fostamatinib a Spleen Tyrosine Kinase InhibitorAnkit Mangla, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
Press Mentions
- What Is Cardiac Angiosarcoma?November 29th, 2021
- Favourable Response More Likely with Neoadjuvant Dual Immune Checkpoint Inhibitor Than with Anti-PD1 Therapy Alone, but the Occurrence of Adverse Events Is Also HigherApril 11th, 2024
- Jimmy Buffett’s Death from Rare Skin Cancer Is a Reminder to Protect Skin from the SunSeptember 7th, 2023
Professional Memberships
- Member
- Member
- Society for immunotherapy in cancerMember
Other Languages
- Hindi
Hospital Affiliations
- University Hospitals Cleveland Medical CenterCleveland, Ohio
External Links
- Researchgate Profilehttps://www.researchgate.net/profile/Ankit_Mangla
- Google scholarhttps://scholar.google.com/citations?user=4Ag5MgUAAAAJ&hl=en
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: